Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

The androgen receptor regulates a druggable translational regulon in advanced prostate cancer.

Liu Y, Horn JL, Banda K, Goodman AZ, Lim Y, Jana S, Arora S, Germanos AA, Wen L, Hardin WR, Yang YC, Coleman IM, Tharakan RG, Cai EY, Uo T, Pillai SPS, Corey E, Morrissey C, Chen Y, Carver BS, Plymate SR, Beronja S, Nelson PS, Hsieh AC.

Sci Transl Med. 2019 Jul 31;11(503). pii: eaaw4993. doi: 10.1126/scitranslmed.aaw4993.

2.

Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes.

Mao N, Gao D, Hu W, Hieronymus H, Wang S, Lee YS, Lee C, Choi D, Gopalan A, Chen Y, Carver BS.

Mol Cancer Ther. 2019 Sep;18(9):1577-1586. doi: 10.1158/1535-7163.MCT-18-1386. Epub 2019 Jul 11.

PMID:
31296553
3.

Surgical Management of Patients with Advanced Germ Cell Tumors Following Salvage Chemotherapy: Memorial Sloan Kettering Cancer Center (MSKCC) Experience.

Miller MI, Feifer A, Feldman DR, Carver BS, Bosl GJ, Motzer RJ, Bajorin DF, Sheinfeld J.

Urology. 2019 Feb;124:174-178. doi: 10.1016/j.urology.2018.09.024. Epub 2018 Oct 6.

PMID:
30296502
4.

Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor.

Pietzak EJ, Assel M, Becerra MF, Tennenbaum D, Feldman DR, Bajorin DF, Motzer RJ, Bosl GJ, Carver BS, Sjoberg DD, Sheinfeld J.

Urology. 2018 Aug;118:114-118. doi: 10.1016/j.urology.2018.04.009. Epub 2018 Apr 25.

PMID:
29704586
5.

A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer.

Graham L, Banda K, Torres A, Carver BS, Chen Y, Pisano K, Shelkey G, Curley T, Scher HI, Lotan TL, Hsieh AC, Rathkopf DE.

Invest New Drugs. 2018 Jun;36(3):458-467. doi: 10.1007/s10637-018-0578-9. Epub 2018 Mar 6.

6.

Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen.

Dowling CM, Assel M, Musser JE, Meeks JJ, Sjoberg DD, Bosl G, Motzer R, Bajorin D, Feldman D, Carver BS, Sheinfeld J.

Urology. 2018 Apr;114:133-138. doi: 10.1016/j.urology.2018.01.014. Epub 2018 Feb 2.

PMID:
29410311
7.

Correction: Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors.

Kaittanis C, Andreou C, Hieronymus H, Mao N, Foss CA, Eiber M, Weirich G, Panchal P, Gopalan A, Zurita J, Achilefu S, Chiosis G, Ponomarev V, Schwaiger M, Carver BS, Pomper MG, Grimm J.

J Exp Med. 2018 Jan 2;215(1):377. doi: 10.1084/jem.2017105211212017c. Epub 2017 Nov 28. No abstract available.

8.

Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors.

Kaittanis C, Andreou C, Hieronymus H, Mao N, Foss CA, Eiber M, Weirich G, Panchal P, Gopalan A, Zurita J, Achilefu S, Chiosis G, Ponomarev V, Schwaiger M, Carver BS, Pomper MG, Grimm J.

J Exp Med. 2018 Jan 2;215(1):159-175. doi: 10.1084/jem.20171052. Epub 2017 Nov 15. Erratum in: J Exp Med. 2017 Nov 28;:.

9.

Deletion of 3p13-14 locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis.

Hieronymus H, Iaquinta PJ, Wongvipat J, Gopalan A, Murali R, Mao N, Carver BS, Sawyers CL.

Nat Commun. 2017 Oct 20;8(1):1081. doi: 10.1038/s41467-017-01198-9.

10.

Malignant Mesothelioma of the Tunica Vaginalis Testis: Outcomes Following Surgical Management Beyond Radical Orchiectomy.

Recabal P, Rosenzweig B, Bazzi WM, Carver BS, Sheinfeld J.

Urology. 2017 Sep;107:166-170. doi: 10.1016/j.urology.2017.04.011. Epub 2017 Apr 14.

11.

Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy.

Kopp RP, Chevinsky M, Bernstein M, Bosl G, Motzer R, Bajorin D, Feldman D, Carver BS, Sheinfeld J.

Urology. 2017 May;103:154-160. doi: 10.1016/j.urology.2016.10.018. Epub 2016 Nov 2.

12.

Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors.

Mano R, Becerra MF, Carver BS, Bosl GJ, Motzer RJ, Bajorin DF, Feldman DR, Sheinfeld J.

J Urol. 2017 Feb;197(2):391-397. doi: 10.1016/j.juro.2016.09.113. Epub 2016 Oct 5.

13.

Pelvic Lymph Node Dissection in Patients Treated for Testis Cancer: The Memorial Sloan Kettering Cancer Center Experience.

Alanee SR, Carver BS, Feldman DR, Motzer RJ, Bosl GJ, Sheinfeld J.

Urology. 2016 Sep;95:128-31. doi: 10.1016/j.urology.2016.05.014. Epub 2016 May 25.

14.

Defining and Targeting the Oncogenic Drivers of Neuroendocrine Prostate Cancer.

Carver BS.

Cancer Cell. 2016 Apr 11;29(4):431-432. doi: 10.1016/j.ccell.2016.03.023.

15.

Late Relapse of Testicular Germ Cell Tumors.

O'Shaughnessy MJ, Feldman DR, Carver BS, Sheinfeld J.

Urol Clin North Am. 2015 Aug;42(3):359-68. doi: 10.1016/j.ucl.2015.04.010. Epub 2015 Jun 16. Review.

PMID:
26216823
16.

Desperation Postchemotherapy Retroperitoneal Lymph Node Dissection for Metastatic Germ Cell Tumors.

Carver BS.

Urol Clin North Am. 2015 Aug;42(3):343-6. doi: 10.1016/j.ucl.2015.04.008. Epub 2015 Jun 6. Review.

PMID:
26216821
17.

Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.

Lunardi A, Varmeh S, Chen M, Taulli R, Guarnerio J, Ala U, Seitzer N, Ishikawa T, Carver BS, Hobbs RM, Quarantotti V, Ng C, Berger AH, Nardella C, Poliseno L, Montironi R, Castillo-Martin M, Cordon-Cardo C, Signoretti S, Pandolfi PP.

Cancer Discov. 2015 May;5(5):550-63. doi: 10.1158/2159-8290.CD-13-1050. Epub 2015 Feb 4.

18.

Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.

Schwartz S, Wongvipat J, Trigwell CB, Hancox U, Carver BS, Rodrik-Outmezguine V, Will M, Yellen P, de Stanchina E, Baselga J, Scher HI, Barry ST, Sawyers CL, Chandarlapaty S, Rosen N.

Cancer Cell. 2015 Jan 12;27(1):109-22. doi: 10.1016/j.ccell.2014.11.008. Epub 2014 Dec 24.

19.

Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling.

Wanjala J, Taylor BS, Chapinski C, Hieronymus H, Wongvipat J, Chen Y, Nanjangud GJ, Schultz N, Xie Y, Liu S, Lu W, Yang Q, Sander C, Chen Z, Sawyers CL, Carver BS.

Mol Cancer Ther. 2015 Jan;14(1):278-88. doi: 10.1158/1535-7163.MCT-14-0542-T. Epub 2014 Nov 7.

20.

Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries.

Doran MG, Spratt DE, Wongvipat J, Ulmert D, Carver BS, Sawyers CL, Evans MJ.

Mol Imaging. 2014;13. doi: 10.2310/7290.2014.00026.

21.

Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors.

Kundu SD, Feldman DR, Carver BS, Gupta A, Bosl GJ, Motzer RJ, Bajorin DF, Sheinfeld J.

J Urol. 2015 Feb;193(2):513-8. doi: 10.1016/j.juro.2014.08.081. Epub 2014 Aug 20.

22.

Strategies for targeting the androgen receptor axis in prostate cancer.

Carver BS.

Drug Discov Today. 2014 Sep;19(9):1493-7. doi: 10.1016/j.drudis.2014.07.008. Epub 2014 Aug 10. Review.

PMID:
25107669
23.

Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer.

Xie Y, Lu W, Liu S, Yang Q, Carver BS, Li E, Wang Y, Fazli L, Gleave M, Chen Z.

Mol Endocrinol. 2014 Oct;28(10):1629-39. doi: 10.1210/me.2014-1078. Epub 2014 Aug 6.

24.

Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer.

Nazarian A, Lawlor K, Yi SS, Philip J, Ghosh M, Yaneva M, Villanueva J, Saghatelian A, Assel M, Vickers AJ, Eastham JA, Scher HI, Carver BS, Lilja H, Tempst P.

Mol Cell Proteomics. 2014 Nov;13(11):3082-96. doi: 10.1074/mcp.M114.038836. Epub 2014 Jul 23.

25.

Copy number alteration burden predicts prostate cancer relapse.

Hieronymus H, Schultz N, Gopalan A, Carver BS, Chang MT, Xiao Y, Heguy A, Huberman K, Bernstein M, Assel M, Murali R, Vickers A, Scardino PT, Sander C, Reuter V, Taylor BS, Sawyers CL.

Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11139-44. doi: 10.1073/pnas.1411446111. Epub 2014 Jul 14.

26.

Slug regulates E-cadherin repression via p19Arf in prostate tumorigenesis.

Xie Y, Liu S, Lu W, Yang Q, Williams KD, Binhazim AA, Carver BS, Matusik RJ, Chen Z.

Mol Oncol. 2014 Oct;8(7):1355-64. doi: 10.1016/j.molonc.2014.05.006. Epub 2014 May 21.

27.

Clinical outcomes of local and metastatic testicular sex cord-stromal tumors.

Silberstein JL, Bazzi WM, Vertosick E, Carver BS, Bosl GJ, Feldman DR, Bajorin DF, Motzer RJ, Al-Ahmadie H, Reuter VE, Sheinfeld J.

J Urol. 2014 Aug;192(2):415-9. doi: 10.1016/j.juro.2014.01.104. Epub 2014 Feb 8.

28.

Primary retroperitoneal lymph node dissection in low-stage testicular germ cell tumors: a detailed pathologic study with clinical outcome analysis with special emphasis on patients who did not receive adjuvant therapy.

Al-Ahmadie HA, Carver BS, Cronin AM, Olgac S, Tickoo SK, Fine SW, Gopalan A, Stasi J, Rabbani F, Bosl GJ, Sheinfeld J, Reuter VE.

Urology. 2013 Dec;82(6):1341-6. doi: 10.1016/j.urology.2013.04.082. Epub 2013 Oct 2.

PMID:
24094656
29.

Androgen receptor signaling regulates DNA repair in prostate cancers.

Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, Arora VK, Yen WF, Cai L, Zheng D, Carver BS, Chen Y, Watson PA, Shah NP, Fujisawa S, Goglia AG, Gopalan A, Hieronymus H, Wongvipat J, Scardino PT, Zelefsky MJ, Jasin M, Chaudhuri J, Powell SN, Sawyers CL.

Cancer Discov. 2013 Nov;3(11):1245-53. doi: 10.1158/2159-8290.CD-13-0172. Epub 2013 Sep 11.

30.

Translating insights of AR signaling from mouse models.

Carver BS.

Transl Androl Urol. 2013 Sep;2(3):197-201. doi: 10.3978/j.issn.2223-4683.2013.09.17. Review.

31.

ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss.

Chen Y, Chi P, Rockowitz S, Iaquinta PJ, Shamu T, Shukla S, Gao D, Sirota I, Carver BS, Wongvipat J, Scher HI, Zheng D, Sawyers CL.

Nat Med. 2013 Aug;19(8):1023-9. doi: 10.1038/nm.3216. Epub 2013 Jun 30.

32.

Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site.

Masterson TA, Carver BS, Shayegan B, Feldman DR, Motzer RJ, Bosl GJ, Sheinfeld J.

Urology. 2012 May;79(5):1079-84. doi: 10.1016/j.urology.2011.11.090. Epub 2012 Mar 23.

PMID:
22446341
33.

Impact of age on clinicopathological outcomes and recurrence-free survival after the surgical management of nonseminomatous germ cell tumour.

Masterson TA, Carver BS, Abel EJ, Pettus JA, Bosl GJ, Sheinfeld J.

BJU Int. 2012 Oct;110(7):950-5. doi: 10.1111/j.1464-410X.2012.10947.x. Epub 2012 Mar 6.

34.

Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer.

Masterson TA, Shayegan B, Carver BS, Bajorin DF, Feldman DR, Motzer RJ, Bosl GJ, Sheinfeld J.

Urology. 2012 Jan;79(1):156-9. doi: 10.1016/j.urology.2011.09.038.

PMID:
22202548
35.

Body mass index is associated with higher lymph node counts during retroperitoneal lymph node dissection.

Thompson RH, Carver BS, Bosl GJ, Bajorin D, Motzer R, Feldman D, Reuter VE, Sheinfeld J.

Urology. 2012 Feb;79(2):361-4. doi: 10.1016/j.urology.2011.04.050. Epub 2011 Dec 14.

36.

Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression.

Chen M, Pratt CP, Zeeman ME, Schultz N, Taylor BS, O'Neill A, Castillo-Martin M, Nowak DG, Naguib A, Grace DM, Murn J, Navin N, Atwal GS, Sander C, Gerald WL, Cordon-Cardo C, Newton AC, Carver BS, Trotman LC.

Cancer Cell. 2011 Aug 16;20(2):173-86. doi: 10.1016/j.ccr.2011.07.013.

37.

Retroperitoneal histologic findings of patients with elevated serum alpha-fetoprotein and pure seminoma at orchiectomy.

Kundu SD, Carver BS, Sheinfeld J.

Urology. 2011 Oct;78(4):844-7. doi: 10.1016/j.urology.2011.02.002. Epub 2011 Jul 22.

38.

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.

Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL.

Cancer Cell. 2011 May 17;19(5):575-86. doi: 10.1016/j.ccr.2011.04.008.

39.

Postchemotherapy surgery for germ cell tumors of the testis.

Carver BS, Sheinfeld J.

Curr Opin Oncol. 2011 May;23(3):271-4. doi: 10.1097/CCO.0b013e32834579d9. Review.

PMID:
21415749
40.

MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors.

Clegg NJ, Couto SS, Wongvipat J, Hieronymus H, Carver BS, Taylor BS, Ellwood-Yen K, Gerald WL, Sander C, Sawyers CL.

PLoS One. 2011 Mar 4;6(3):e17449. doi: 10.1371/journal.pone.0017449.

41.

Contemporary lymph node counts during primary retroperitoneal lymph node dissection.

Thompson RH, Carver BS, Bosl GJ, Bajorin D, Motzer R, Feldman DR, Reuter VE, Sheinfeld J.

Urology. 2011 Feb;77(2):368-72. doi: 10.1016/j.urology.2010.05.020. Epub 2010 Dec 15.

42.

Evaluation of lymph node counts in primary retroperitoneal lymph node dissection.

Thompson RH, Carver BS, Bosl GJ, Bajorin D, Motzer R, Feldman D, Reuter VE, Sheinfeld J.

Cancer. 2010 Nov 15;116(22):5243-50. doi: 10.1002/cncr.25266.

43.

Integrative genomic profiling of human prostate cancer.

Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL.

Cancer Cell. 2010 Jul 13;18(1):11-22. doi: 10.1016/j.ccr.2010.05.026. Epub 2010 Jun 24.

44.

Surgery for retroperitoneal relapse in the setting of a prior retroperitoneal lymph node dissection for germ cell tumor.

Gotto GT, Carver BS, Sogani P, Sheinfeld J.

Indian J Urol. 2010 Jan-Mar;26(1):102-7. doi: 10.4103/0970-1591.60452.

45.

The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer.

Carver BS, Cronin AM, Eggener S, Savage CJ, Motzer RJ, Bajorin D, Bosl GJ, Sheinfeld J.

Urology. 2010 Jun;75(6):1431-5. doi: 10.1016/j.urology.2009.11.076. Epub 2010 Mar 17.

46.

Differential p53-independent outcomes of p19(Arf) loss in oncogenesis.

Chen Z, Carracedo A, Lin HK, Koutcher JA, Behrendt N, Egia A, Alimonti A, Carver BS, Gerald W, Teruya-Feldstein J, Loda M, Pandolfi PP.

Sci Signal. 2009 Aug 18;2(84):ra44. doi: 10.1126/scisignal.2000053.

47.

Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy.

Stephenson AJ, Wood DP, Kattan MW, Klein EA, Scardino PT, Eastham JA, Carver BS.

J Urol. 2009 Oct;182(4):1357-63. doi: 10.1016/j.juro.2009.06.046. Epub 2009 Aug 14.

PMID:
19683274
48.

Against: The case for cytoreductive nephrectomy for the management of metastatic renal cell carcinoma.

Carver BS.

J Urol. 2009 Sep;182(3):833-4. doi: 10.1016/j.juro.2009.06.077. Epub 2009 Jul 18. No abstract available.

PMID:
19616224
49.

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP.

Nat Genet. 2009 May;41(5):619-24. doi: 10.1038/ng.370. Epub 2009 Apr 26.

50.

Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.

King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, Gerald WL, Sawyers CL.

Nat Genet. 2009 May;41(5):524-6. doi: 10.1038/ng.371. Epub 2009 Apr 26.

Supplemental Content

Loading ...
Support Center